# Cell-manufacturing outcomes and nonconforming products

Source: https://onco.cc/terms/cell-manufacturing-outcomes/  
OnCo record `cell-manufacturing-outcomes` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Making a cell product, meeting its quality requirements, shipping it and treating a person are different outcomes. A report's definition and denominator determine what its success rate means.

## Summary

A process can stop without a product, produce a nonconforming lot, make a conforming product that is never shipped, or supply material that is never infused. Out-of-specification means at least one stated requirement was missed; it does not determine which attribute, severity or disposition applies. Studies sometimes include such lots within manufacturing failure, while others report separate categories. Keep orders, collections, runs, batches, people, cancellations and follow-up with the reported measure.

## Fields

- Kind: Term
- Last checked: 2026-11-09
- Also known as: cell manufacturing failure; out-of-specification cell product; OOS cell product; manufacturing success rate; shipment success rate

## Notes

- In a fictional 100-collection pathway, 94 produce completed products, four of those 94 miss a stated specification, and 85 people are ultimately infused. Completion, conformity and infusion have different numerators and can require different denominators. These invented numbers do not define a standard manufacturing-success metric, describe a real cohort or imply that an out-of-specification product was used.
- Iwamoto's 2025 report covers Japanese tisagenlecleucel manufacturing from August 2019 to July 2023. Its manufacturing-success numerator is batches meeting health-authority release criteria; its shipment-success numerator also includes selected nonconforming products made available for shipment. Both use initiated batches excluding specified cancellations during manufacturing. Cancellation rate instead uses all initiated batches and can include cancellations after receipt. The methods report no formal statistical analysis; observed before/after changes do not isolate a causal process effect.
- The UK National CAR T Panel's 2025 retrospective report uses manufacturing failure to include no product and out-of-specification product. Approved, remanufactured, infused and never-infused people remain separate groups. Its report of no statistically significant outcome differences is not a demonstration of equivalence, and its associations do not establish individual risk or treatment selection.
- Kato's 2025 single-arm Japanese report enrolled 29 people and infused 28, with 23 DLBCL and five ALL recipients. Response was assessed in 15 of the 23 DLBCL recipients; it is not correct to give the evaluable response denominator as all 23. The abstract's batch denominators also differ by missed attribute: low viability 15/24, low dose 8/23 DLBCL and high dose 4/5 ALL. Do not combine those fractions or treat single-arm comparisons as proof of equal safety or efficacy.
- The Kato report's NCT04094311 identifies a specific clinical supply pathway for nonconforming tisagenlecleucel. The captured registry remains a larger recruiting study with no posted results, not just that dated published cohort. Registry design, national supply rules and a report of use do not authorise use of another nonconforming lot or establish a local treatment slot.
- Record the missed specification, test method, material, lot, jurisdiction and programme. Selected access can involve a separate authorised pathway and case-specific quality and clinical assessment; a low-viability miss is not interchangeable with a dose miss or contamination. A conforming product also does not establish patient readiness or clinical benefit.

## Sources

- FDA: CAR T-cell development guidance, January 2024: https://www.fda.gov/media/156896/download
- Iwamoto et al., 2025: Japan manufacturing and shipment definitions: https://pubmed.ncbi.nlm.nih.gov/40066375/
- UK National CAR T Panel, 2025: source-defined manufacturing failure and patient outcomes: https://pubmed.ncbi.nlm.nih.gov/40032870/
- Kato et al., 2025: single-arm nonconforming tisagenlecleucel cohort: https://pubmed.ncbi.nlm.nih.gov/40377509/
- ClinicalTrials.gov: NCT04094311, design and dated registry state: https://clinicaltrials.gov/study/NCT04094311

## Connected records

- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/), [Cell-therapy orchestration and chain-of-identity software](https://onco.cc/technologies/cell-therapy-orchestration-software/), [Cell-therapy release and potency testing](https://onco.cc/technologies/cell-therapy-release-testing/), [Cryopreservation and cell-therapy cold chain](https://onco.cc/technologies/cell-therapy-cold-chain/)
- terms: [Apheresis (leukapheresis)](https://onco.cc/terms/apheresis/), [Cell-product chain of identity and custody](https://onco.cc/terms/chain-of-identity-and-custody/), [Ex vivo cell expansion](https://onco.cc/terms/ex-vivo-cell-expansion/), [Vein-to-vein time and manufacturing slots](https://onco.cc/terms/vein-to-vein-time/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)

---
JSON: https://onco.cc/api/v1/entities/cell-manufacturing-outcomes.json